Testing ATI-2231 Treatment for Advanced Solid Tumor Malignancies

Withdrawn Phase 1 NCT05791474

Study Description

ATI-2231 is being researched in a first-in-human study to determine the recommended Phase II dose and effectiveness for treating advanced solid tumor malignancies.

Study Details

Registry ID:: NCT05791474
Conditions:: Advanced Solid Tumor, Advanced Solid Tumor Malignancies
Phase:: Phase 1
Start Date:: November 15, 2023
Age Range:: 18–999 years
Healthy Volunteers:: No

Study Locations (4 sites)

Washington University School of Medicine
Saint Louis, MissouriUnited States, United States
Washington University School of Medicine
Saint Louis, MissouriUnited States, United States
Kansas University Medical Center
Kansas City, KansasUnited States, United States
Mayo Clinic
Rochester, MinnesotaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →